Epizyme announces first patient dosed in global clinical program. Dana Farber Cancer Institute and Cincinnati Children's Hospital are the first sites activated for pediatric enrollment.
The study of tazemetostat offers a possible treatment for INI1-negative tumors, including AT/RT, when no other treatments are available. Read More
